Literature DB >> 16026900

Expression of urotensin-II in human coronary atherosclerosis.

Ghada S Hassan1, Stephen A Douglas, Eliot H Ohlstein, Adel Giaid.   

Abstract

The vasoactive peptide urotensin-II (U-II) is best known for its ability to regulate peripheral vascular and cardiac contractile function in vivo, and recent in vitro studies have suggested a role for the peptide in the control of vascular remodeling by inducing smooth muscle proliferation and fibroblast-mediated collagen deposition. Therefore, U-II may play a role in the etiology of atherosclerosis. In the present study we sought to determine the expression of U-II in coronary arteries from patients with coronary atherosclerosis and from normal control subjects, using immunohistochemistry and in situ hybridization. In normal coronary arteries, there was little expression of U-II in all types of cells. In contrast, in patients with coronary atherosclerosis, endothelial expression of U-II was significantly increased in all diseased segments (P<0.05). Greater expression of U-II was noted in endothelial cells of lesions with subendothelial inflammation or fibrofatty lesion compared with that of endothelial cells underlined by dense fibrosis or minimal intimal thickening. Myointimal cells and foam cells also expressed U-II. In most diseased segments, medial smooth muscle cells exhibited moderate expression of U-II. These findings demonstrate upregulation of U-II in endothelial, myointimal and medial smooth muscle cells of atherosclerotic human coronary arteries, and suggest a possible role for U-II in the pathogenesis of coronary atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16026900     DOI: 10.1016/j.peptides.2005.05.028

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  16 in total

1.  Enhancement of vascular smooth muscle cell migration by urotensin II.

Authors:  Satoshi Matsusaka; Ichiro Wakabayashi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-08-01       Impact factor: 3.000

Review 2.  Urotensin-II and cardiovascular diseases.

Authors:  Nicolas Bousette; Adel Giaid
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

3.  Effects of urotensin-II on cytokines in early acute liver failure in mice.

Authors:  Liang-Ming Liu; Liang Zhao; Dong-Yu Liang; Fang-Ping Yu; Chang-Gen Ye; Wen-Juan Tu; Tong Zhu
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

4.  A closer look at the role of urotensin II in the metabolic syndrome.

Authors:  Pierre-Olivier Barrette; Adel Giaid Schwertani
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-28       Impact factor: 5.555

5.  Potential Clinical Implications of the Urotensin II Receptor Antagonists.

Authors:  Philip Tsoukas; Emilie Kane; Adel Giaid
Journal:  Front Pharmacol       Date:  2011-07-22       Impact factor: 5.810

6.  The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats.

Authors:  Juan Zhao; Quan-Xin Yu; Wei Kong; Hai-Cheng Gao; Bo Sun; Ya-Qin Xie; Li-Qun Ren
Journal:  Exp Ther Med       Date:  2013-04-09       Impact factor: 2.447

7.  Urotensin-II system in genetic control of blood pressure and renal function.

Authors:  Radoslaw Debiec; Paraskevi Christofidou; Matthew Denniff; Lisa D Bloomer; Pawel Bogdanski; Lukasz Wojnar; Katarzyna Musialik; Fadi J Charchar; John R Thompson; Dawn Waterworth; Kijoung Song; Peter Vollenweider; Gerard Waeber; Ewa Zukowska-Szczechowska; Nilesh J Samani; David Lambert; Maciej Tomaszewski
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

8.  Urotensin-II Immunoreactivity in Normolipidemic and Hyperlipidemic New Zealand White Rabbits Following Balloon Angioplasty and Stenting.

Authors:  Nicolas Bousette; Fazila Chouiali; Eliot H Ohlstein; Stephen A Douglas; Adel Giaid
Journal:  Int J Biomed Sci       Date:  2007-03

Review 9.  Urotensin II in cardiovascular regulation.

Authors:  Fraser D Russell
Journal:  Vasc Health Risk Manag       Date:  2008

10.  Inhibitory Effect of an Urotensin II Receptor Antagonist on Proinflammatory Activation Induced by Urotensin II in Human Vascular Endothelial Cells.

Authors:  Sung Lyea Park; Bo Kyung Lee; Young-Ae Kim; Byung Ho Lee; Yi-Sook Jung
Journal:  Biomol Ther (Seoul)       Date:  2013-07-30       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.